as on January 28, 2026 at 9:38 pm IST
Day's High
5.52%
Upside
52 Week's Low
52 Week's High
10.34%
Downside
181.29%
Upside
Check Akebia Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$379.5M
EPS (TTM)
0.04
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-7.78
Industry PE ratio
-1.8136016949152542
PEG Ratio
0EBITDA
32.2M
Revenue (TTM)
225.1M
Profit Margin
-7.07%
Return On Equity TTM
-553.45%
Track how Akebia Therapeutics Inc P/E has moved over time to understand its valuation trends.
Akebia Therapeutics Inc in the last 5 years
Lowest (-71.38x)
September 30, 2025
Today (-7.78x)
January 28, 2026
Industry (-1.81x)
January 28, 2026
Highest (39.21x)
December 31, 2025
Today’s Price to Earnings Ratio: -7.78x
Compare market cap, revenue, PE, and other key metrics of Akebia Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $379.5M | -55.91% | -7.78 | -7.07% | |
| NA | $14.4B | NA | NA | 0.00% | |
| BUY | $21.6B | NA | 18.08 | 40.65% | |
| BUY | $46.2B | NA | 22.54 | 13.81% | |
| HOLD | $15.2B | -23.68% | -21.95 | -26.13% |
The Akebia Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Akebia Therapeutics Inc investment value today
Current value as on today
₹69,293
Returns
Returns from Akebia Therapeutics Inc Stock
Dollar Returns*
₹5,974 (+5.97%)
Based on 9 analysts
88.89%
Buy
11.11%
Hold
0.00%
Sell
Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Akebia Therapeutics Inc. Average target price of $5.4
Get share price movements and forecasts by analysts on Akebia Therapeutics Inc.
What analysts predicted
73.15%UPSIDE
Target Price
$5.4
Current Price
$1.45
Analyzed by
9 Analysts
Target
$5.40
Akebia Therapeutics Inc target price $5.4, a slight upside of 73.15% compared to current price of $1.45. According to 9 analysts rating.
Search interest for Akebia Therapeutics Inc Stock has increased by 18% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:18% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
![]()
In the last 7 days, AKBA stock has moved up by 10.2%
Profit Spike
![]()
Netprofit is up for the last 2 quarters, 247.0K → 540.0K (in $), with an average increase of 54.3% per quarter
Against Peers
![]()
In the last 3 years, Regencell Bioscience Holdings Ltd has given 3962.6% return, outperforming this stock by 3837.2%
Against Peers
![]()
In the last 1 year, Regencell Bioscience Holdings Ltd has given 28567.3% return, outperforming this stock by 28601.4%
Revenue Fall
![]()
Revenue is down for the last 2 quarters, 62.47M → 58.76M (in $), with an average decrease of 5.9% per quarter
| Organisation | Akebia Therapeutics Inc |
| Headquarters | 245 First Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Mr. John P. Butler MBA |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Ms. Carolyn Rucci | Senior VP of Legal, General Counsel & Secretary |
Ms. Meredith Bowman | Senior VP & Chief People Officer |
Mr. John P. Butler MBA | CEO, President & Director |
Dr. Steven Keith Burke M.D. | Senior VP and Chief Research & Development Officer |
Mr. Richard C. Malabre | Chief Accounting Officer |
Ms. Tracey Vetterick | Vice President of Portfolio Strategy & Corporate Administration |
Mercedes Carrasco | Senior Director of Investor & Corporate Communications |
Mr. Erik John Ostrowski M.B.A. | Chief Business Officer, Senior VP, CFO & Treasurer |
Mr. Nicholas Grund | Senior VP & Chief Commercial Officer |
Ms. Kimberly Garko | Senior VP & Chief Technical Officer |
Akebia Therapeutics Inc share price today is $1.45 as on . Akebia Therapeutics Inc share today touched a day high of $1.53 and a low of $1.45.
Akebia Therapeutics Inc share touched a 52 week high of $4.08 on and a 52 week low of $1.3 on . Akebia Therapeutics Inc stock price today i.e. is trending at $1.45,which is 64.45% down from its 52 week high and 11.54% up from its 52 week low.
Akebia Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Akebia Therapeutics Inc (AKBA) shares with as little as ₹91.762 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹917.62 in Akebia Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Akebia Therapeutics Inc share’s latest price of $1.45 as on January 28, 2026 at 9:38 pm IST, you will get 6.8966 shares of Akebia Therapeutics Inc. Learn more about
fractional shares .
Akebia Therapeutics Inc stock has given -55.91% share price returns and 25.73% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?